Vimizim

(Elosulfase alfa)

Vimizim

Drug updated on 12/19/2023

Dosage FormInjection (intravenous; 5 mg/5 mL (1 mg/mL))
Drug ClassHydrolytic lysosomal glycosaminoglycan (GAG)-specific enzymes
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Treatment for Mucopolysaccharidosis type IVA (Morquio A syndrome).

Product Monograph / Prescribing Information

Document TitleYearSource
Vimizim (elosulfase alfa) Prescribing Information.2019BioMarin Pharmaceutical Inc., Novato, CA

Randomized Controlled Trials

Clinical Practice Guidelines